These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 4007893)

  • 21. Vecuronium block in the myasthenic patient. Influence of anticholinesterase therapy.
    Baraka A; Taha S; Yazbeck V; Rizkallah P
    Anaesthesia; 1993 Jul; 48(7):588-90. PubMed ID: 8102223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuromuscular blockade.
    Neigh JL
    Surg Clin North Am; 1975 Aug; 55(4):837-50. PubMed ID: 241125
    [No Abstract]   [Full Text] [Related]  

  • 23. Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood.
    Currie D; Lewis RV; McDevitt DG; Nicholson AN; Wright NA
    Br J Clin Pharmacol; 1988 Aug; 26(2):121-8. PubMed ID: 2905148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of pyridostigmine bromide and permethrin, alone or in combination, on response acquisition in male and female rats.
    Van Haaren F; Cody B; Hoy JB; Karlix JL; Schmidt CJ; Tebbett IR; Wielbo D
    Pharmacol Biochem Behav; 2000 Aug; 66(4):739-46. PubMed ID: 10973511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihistamines: impaired performance and the tendency to sleep.
    Nicholson AN; Stone BM
    Eur J Clin Pharmacol; 1986; 30(1):27-32. PubMed ID: 3086105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low concentrations of pyridostigmine prevent soman-induced inhibition of GABAergic transmission in the central nervous system: involvement of muscarinic receptors.
    Santos MD; Pereira EF; Aracava Y; Castro NG; Fawcett WP; Randall WR; Albuquerque EX
    J Pharmacol Exp Ther; 2003 Jan; 304(1):254-65. PubMed ID: 12490599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
    Singer W; Sandroni P; Opfer-Gehrking TL; Suarez GA; Klein CM; Hines S; O'Brien PC; Slezak J; Low PA
    Arch Neurol; 2006 Apr; 63(4):513-8. PubMed ID: 16476804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrethroid decrease in central nervous system from nerve agent pretreatment.
    Buchholz BA; Pawley NH; Vogel JS; Mauthe RJ
    J Appl Toxicol; 1997; 17(4):231-4. PubMed ID: 9285535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrastructural effects of pyridostigmine on neuromuscular junctions in rat diaphragm.
    Hudson CS; Foster RE; Kahng MW
    Neurotoxicology; 1986; 7(1):167-85. PubMed ID: 3714119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combined effects of pyridostigmine and chronic stress on brain cortical and blood acetylcholinesterase, corticosterone, prolactin and alternation performance in rats.
    Kant GJ; Bauman RA; Feaster SR; Anderson SM; Saviolakis GA; Garcia GE
    Pharmacol Biochem Behav; 2001; 70(2-3):209-18. PubMed ID: 11701190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protection of human muscle acetylcholinesterase from soman by pyridostigmine bromide.
    Maselli RA; Henderson JD; Ng J; Follette D; Graves G; Wilson BW
    Muscle Nerve; 2011 Apr; 43(4):591-5. PubMed ID: 21404290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resting and reflex heart rate responses during cholinergic stimulation with pyridostigmine in humans.
    Nóbrega AC; Carvalho AC; Bastos BG
    Braz J Med Biol Res; 1996 Nov; 29(11):1461-5. PubMed ID: 9196546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyridostigmine blunts the increases in myocardial oxygen demand elicited by the stimulation of the central nervous system in anesthetized rats.
    Grabe-Guimarães A; Alves LM; Tibiriçá E; Nóbrega AC
    Clin Auton Res; 1999 Apr; 9(2):83-9. PubMed ID: 10225612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial.
    Schreglmann SR; Büchele F; Sommerauer M; Epprecht L; Kägi G; Hägele-Link S; Götze O; Zimmerli L; Waldvogel D; Baumann CR
    Eur J Neurol; 2017 Apr; 24(4):545-551. PubMed ID: 28224720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of nerve agent pre-treatment with pyridostigmine on the duration of action of suxamethonium.
    Heath KJ; Niemiro LA; Gosden EA; Restall J
    Anaesthesia; 1996 Apr; 51(4):404. PubMed ID: 8686841
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of computerized psychomotor testing in determining CNS effects of drugs.
    Berchou R; Block RI
    Percept Mot Skills; 1983 Dec; 57(3 Pt 1):691-700. PubMed ID: 6664751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on the possible central effects in man of a neuropeptide (ACTH 4-9 analogue).
    Nicholson AN; Stone BM; Jones SJ
    Eur J Clin Pharmacol; 1984; 27(5):561-5. PubMed ID: 6097457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A test for the assessment of the duration of the action of neostigmine and of the relative potencies of various anticholinesterases using the pupil of the mouse.
    Schneider R
    J Pharm Pharmacol; 1970 Apr; 22(4):298-301. PubMed ID: 4392572
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiac function during mental stress: cholinergic modulation with pyridostigmine in healthy subjects.
    Sant'anna ID; de Sousa EB; de Moraes AV; Loures DL; Mesquita ET; da Nóbrega AC
    Clin Sci (Lond); 2003 Aug; 105(2):161-5. PubMed ID: 12627998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pyridostigmine bromide alters locomotion and thigmotaxis of rats: gender effects.
    Hoy JB; Cody BA; Karlix JL; Schmidt CJ; Tebbett IR; Toffollo S; Van Haaren F; Wielbo D
    Pharmacol Biochem Behav; 1999 Jul; 63(3):401-6. PubMed ID: 10418780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.